Beta-cryptoxanthin compositions and methods are described for the management of cardiometabolic syndrome and associated risk factors, in a subject, in need thereof. Methods herein are directed to identifying such subject at risk of developing cardiometabolic syndrome and administering beta-cryptoxanthin composition to assess the condition of an organ. Compositions and methods herein can effectively reduce risk factors of cardiometabolic syndrome, such as hyperlipidemia, insulin resistance, obesity, diabetes, atherosclerosis and/or related cardiovascular disorders. Beta-cryptoxanthin compositions and methods herein can reduce body weight, body fat, glucose levels, and free fatty acids, when administered in effective amounts. The compositions and methods herein can also reduce oxidative stress on organs such as the eye and liver and/or reduce inflammatory and/or oxidative markers, when administered to subjects in need thereof.

Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.

The present invention relates to methods for determining the presence of pathologic amylin in a subject with diabetes or pre-diabetes. The method includes obtaining a skin sample from a subject and determining if there is pathologic amylin present in the skin sample.

Provided is a catalase inhibitor comprising a compound represented by formula (I):

##STR00001##

wherein R.sub.1 to R.sub.4 independently represent a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a carbonyl group, or a hydrocarbon group having 1 to 4 carbon atoms, wherein the hydrocarbon group may have at least one substituent selected from the group consisting of a halogen atom, an amino group, a hydroxyl group and a carbonyl group; and X.sup. represents an anionic chemical species.

The present disclosure comprises a device and accompanying method for determining the presence or absence of Methicillin-resistant Staphylococcus aureus in a sample. The disclosure includes the following elements: (1) a lateral flow strip for microfluidic manipulation of a sample; (2) a cassette device for containing the lateral flow strip and enabling interface with a detection device; (3) a cassette handler; (4) a luminous reagent delivery device; and (5) an electromagnetic radiation detection device capable of converting chemiluminescent radiation from the lateral flow strip into an output for a user.

Method for detecting a urinary tract infection (UTI) in a subject comprising determining levels of one or more biomarkers selected from MMP8, HNE, Cystatin C, MMP9, HSA, IL-8, interleukin-6 (IL-6), interleukin-1 beta (IL-1b), fibrinogen, RBP4, active MMP9 and MMP2, NGAL, Desmosine, MPO and CRP in a urine sample obtained from the subject. The determined levels may then be compared with a threshold level, wherein increased levels of at least one of the biomarkers in the urine sample relative to the threshold level is indicative of the presence of a urinary tract infection. Methods for monitoring a UTI and monitoring treatment of a UTI are also provided as are companion systems or test kits.

A biological toxicity test method for evaluating an ecological safety of an advanced oxidation process comprising the following steps: (1) collecting (preparing) a waste water to be determined; (2) collecting the waste water and a tap water after the advanced oxidation process treatment; (3) subjecting Koi (Cyprinus carpio haematopterus) to the water after treatment for exposure to poison; (4) Determining an anti-oxidation enzyme activity of a liver of the Koi after exposure; (5) Data analyzing. By comparing the changes of liver enzyme activities in different water, the present method evaluates the toxicity changes of micro-pollutant containing water before and after treatment, which fills in the gap of the ecological risk assessment for advanced oxidation technology.

Enzyme compositions including lactate responsive enzyme and stabilizing agent, including electrodes, sensors, and systems having the same. The stabilizing agent stabilizes the lactate responsive enzyme in a manner sufficient to increase sensitivity to lactate, such as for use in in vivo detection of lactate. In some compositions the lactate responsive enzyme is lactate oxidase and the sensor includes a heterocycle-containing polymer and a crosslinker.

The disclosure provides methods and materials for detecting endogenous IgA antibodies to one or more, or all, of OmpC (ACA), Ki67 (AKiA), TK1, integrin (AINTA) and keratin (AKERA), which are useful to diagnose and distinguish chronic enteropathies, e.g. gastrointestinal neoplasms, e.g., gastrointestinal lymphoma, and, inflammatory conditions, e g inflammatory bowel disease, in felines.

The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a dihydroorotate dehydrogenase (DHODH) inhibitor, wherein the cancer has an altered glutathione peroxidase 4 (GPX4) expression as compared to a control sample. The present disclosure also provides methods of treating a subject with a dihydroorotate dehydrogenase (DHODH) inhibitor where the subject's GPX4 expression is low as compared to a control sample or with a DHODH inhibitor and a ferroptosis inducer where the subject's GPX4 expression is high as compared to a control sample.